FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:KIF11-GRB14

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: KIF11-GRB14
FusionPDB ID: 42520
FusionGDB2.0 ID: 42520
HgeneTgene
Gene symbol

KIF11

GRB14

Gene ID

3832

2888

Gene namekinesin family member 11growth factor receptor bound protein 14
SynonymsEG5|HKSP|KNSL1|MCLMR|TRIP5-
Cytomap

10q23.33

2q24.3

Type of geneprotein-codingprotein-coding
Descriptionkinesin-like protein KIF11TR-interacting protein 5TRIP-5kinesin-like protein 1kinesin-like spindle protein HKSPkinesin-related motor protein Eg5thyroid receptor-interacting protein 5growth factor receptor-bound protein 14GRB14 adapter protein
Modification date2020032920200313
UniProtAcc

P52732

Main function of 5'-partner protein: FUNCTION: Motor protein required for establishing a bipolar spindle during mitosis (PubMed:19001501). Required in non-mitotic cells for transport of secretory proteins from the Golgi complex to the cell surface (PubMed:23857769). {ECO:0000269|PubMed:19001501, ECO:0000269|PubMed:23857769}.

Q14449

Main function of 5'-partner protein: FUNCTION: Adapter protein which modulates coupling of cell surface receptor kinases with specific signaling pathways. Binds to, and suppresses signals from, the activated insulin receptor (INSR). Potent inhibitor of insulin-stimulated MAPK3 phosphorylation. Plays a critical role regulating PDPK1 membrane translocation in response to insulin stimulation and serves as an adapter protein to recruit PDPK1 to activated insulin receptor, thus promoting PKB/AKT1 phosphorylation and transduction of the insulin signal. {ECO:0000269|PubMed:15210700, ECO:0000269|PubMed:19648926}.
Ensembl transtripts involved in fusion geneENST idsENST00000260731, ENST00000497306, 
ENST00000263915, ENST00000543549, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score10 X 9 X 5=4505 X 7 X 4=140
# samples 109
** MAII scorelog2(10/450*10)=-2.16992500144231
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(9/140*10)=-0.637429920615292
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: KIF11 [Title/Abstract] AND GRB14 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: KIF11 [Title/Abstract] AND GRB14 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)KIF11(94397302)-GRB14(165358845), # samples:1
Anticipated loss of major functional domain due to fusion event.KIF11-GRB14 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
KIF11-GRB14 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
KIF11-GRB14 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
KIF11-GRB14 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneKIF11

GO:0090307

mitotic spindle assembly

19001501



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:94397302/chr2:165358845)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across KIF11 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across GRB14 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000260731KIF11chr1094397302+ENST00000263915GRB14chr2165358845-30702250122849945
ENST00000260731KIF11chr1094397302+ENST00000543549GRB14chr2165358845-30632250122849945

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000260731ENST00000263915KIF11chr1094397302+GRB14chr2165358845-0.0005323080.9994677
ENST00000260731ENST00000543549KIF11chr1094397302+GRB14chr2165358845-0.0005377980.9994622

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for KIF11-GRB14

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
KIF11chr1094397302GRB14chr21653588452250745LTEDLKTIKQTHSQYGMQLYQNYMHP

Top

Potential FusionNeoAntigen Information of KIF11-GRB14 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
KIF11-GRB14_94397302_165358845.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:01SQYGMQLY0.99970.76451220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:25SQYGMQLY0.99520.80671220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:03IKQTHSQY0.95020.5389715
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:03SQYGMQLY0.94140.6051220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:01TIKQTHSQY0.99960.8451615
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:01THSQYGMQL0.99940.94441019
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:25TIKQTHSQY0.99910.8443615
KIF11-GRB14chr1094397302chr21653588452250HLA-B38:01THSQYGMQL0.99860.97721019
KIF11-GRB14chr1094397302chr21653588452250HLA-B38:02THSQYGMQL0.99860.98181019
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:13THSQYGMQL0.99840.97271019
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:24THSQYGMQL0.99830.71991019
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:06THSQYGMQL0.99820.92521019
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:02TIKQTHSQY0.9980.874615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:10THSQYGMQL0.99140.69671019
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:17HSQYGMQLY0.99040.8441120
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:16HSQYGMQLY0.95950.62351120
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:37THSQYGMQL0.94460.70491019
KIF11-GRB14chr1094397302chr21653588452250HLA-B14:01THSQYGMQL0.94350.95131019
KIF11-GRB14chr1094397302chr21653588452250HLA-B14:02THSQYGMQL0.94350.95131019
KIF11-GRB14chr1094397302chr21653588452250HLA-B58:02HSQYGMQLY0.92620.84381120
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:03TIKQTHSQY0.89770.662615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:18THSQYGMQL0.76050.79221019
KIF11-GRB14chr1094397302chr21653588452250HLA-B13:01KQTHSQYGM0.47240.9345817
KIF11-GRB14chr1094397302chr21653588452250HLA-B48:01THSQYGMQL0.20440.70111019
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:01KTIKQTHSQY0.99960.8918515
KIF11-GRB14chr1094397302chr21653588452250HLA-B57:01KTIKQTHSQY0.99950.9634515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:25KTIKQTHSQY0.99930.9259515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:17KTIKQTHSQY0.99680.8737515
KIF11-GRB14chr1094397302chr21653588452250HLA-B58:02KTIKQTHSQY0.99660.8942515
KIF11-GRB14chr1094397302chr21653588452250HLA-B58:01KTIKQTHSQY0.98880.9266515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:16KTIKQTHSQY0.98330.7606515
KIF11-GRB14chr1094397302chr21653588452250HLA-A30:08KTIKQTHSQY0.90470.9297515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:18THSQYGMQLY0.87410.56381020
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:24QTHSQYGMQL0.7510.8411919
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:10QTHSQYGMQL0.59760.5369919
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:01QTHSQYGMQL0.53990.9492919
KIF11-GRB14chr1094397302chr21653588452250HLA-A32:13KTIKQTHSQY0.51030.9663515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:37QTHSQYGMQL0.40650.5175919
KIF11-GRB14chr1094397302chr21653588452250HLA-B38:02QTHSQYGMQL0.28070.9791919
KIF11-GRB14chr1094397302chr21653588452250HLA-B38:01QTHSQYGMQL0.2670.9754919
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:01SQYGMQLYQNY0.99990.82041223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:25SQYGMQLYQNY0.99350.83591223
KIF11-GRB14chr1094397302chr21653588452250HLA-B48:01KQTHSQYGMQL0.98740.7875819
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:03SQYGMQLYQNY0.81210.69321223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:05SQYGMQLY0.98490.77121220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:04SQYGMQLY0.97370.7881220
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:09THSQYGMQL0.99940.88761019
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:12THSQYGMQL0.99930.94911019
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:05THSQYGMQL0.99870.94591019
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:07TIKQTHSQY0.99820.6305615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:21TIKQTHSQY0.99780.8136615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:05TIKQTHSQY0.96110.8016615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:04TIKQTHSQY0.94850.875615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:31TIKQTHSQY0.92240.816615
KIF11-GRB14chr1094397302chr21653588452250HLA-C15:04HSQYGMQLY0.91920.73531120
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:95THSQYGMQL0.79090.71971019
KIF11-GRB14chr1094397302chr21653588452250HLA-C15:04TIKQTHSQY0.74780.844615
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:05THSQYGMQL0.73850.95561019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:27THSQYGMQL0.72530.9571019
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:08THSQYGMQL0.71270.95171019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:29THSQYGMQL0.66430.9331019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:13THSQYGMQL0.66430.93171019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:19THSQYGMQL0.56050.80121019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:67THSQYGMQL0.54110.96031019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:80THSQYGMQL0.54110.96031019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:10THSQYGMQL0.51380.96741019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:46THSQYGMQL0.45430.92361019
KIF11-GRB14chr1094397302chr21653588452250HLA-B14:03THSQYGMQL0.40060.92791019
KIF11-GRB14chr1094397302chr21653588452250HLA-C03:14TIKQTHSQY0.19840.9658615
KIF11-GRB14chr1094397302chr21653588452250HLA-C12:12HSQYGMQLY0.05050.82111120
KIF11-GRB14chr1094397302chr21653588452250HLA-B48:03THSQYGMQL0.03950.58711019
KIF11-GRB14chr1094397302chr21653588452250HLA-C12:16THSQYGMQL0.02750.95541019
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:07KTIKQTHSQY0.99930.7047515
KIF11-GRB14chr1094397302chr21653588452250HLA-C15:04KTIKQTHSQY0.99210.8866515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:04KTIKQTHSQY0.98230.9076515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:05KTIKQTHSQY0.97230.8517515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:21THSQYGMQLY0.91610.81311020
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:09QTHSQYGMQL0.6190.8873919
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:05QTHSQYGMQL0.2860.9436919
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:07SQYGMQLYQNY0.99950.51811223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:04SQYGMQLYQNY0.99610.861223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:05SQYGMQLYQNY0.96660.84911223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:125SQYGMQLY0.99970.76451220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:135SQYGMQLY0.99970.78981220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:27SQYGMQLY0.99970.77121220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:33SQYGMQLY0.99970.76451220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:34SQYGMQLY0.99970.76451220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:50SQYGMQLY0.99960.72491220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:24SQYGMQLY0.99940.741220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:35SQYGMQLY0.99880.68591220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:12SQYGMQLY0.99850.68251220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:53SQYGMQLY0.99840.71121220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:39SQYGMQLY0.9950.69381220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:54SQYGMQLY0.99370.68491220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:20SQYGMQLY0.98480.84551220
KIF11-GRB14chr1094397302chr21653588452250HLA-B35:28SQYGMQLY0.97880.87521220
KIF11-GRB14chr1094397302chr21653588452250HLA-B35:20SQYGMQLY0.9410.89491220
KIF11-GRB14chr1094397302chr21653588452250HLA-B18:04SQYGMQLY0.8980.87351220
KIF11-GRB14chr1094397302chr21653588452250HLA-B18:06SQYGMQLY0.87540.83671220
KIF11-GRB14chr1094397302chr21653588452250HLA-C16:01HSQYGMQL0.82510.98491119
KIF11-GRB14chr1094397302chr21653588452250HLA-B48:02SQYGMQLY0.78420.86041220
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:125TIKQTHSQY0.99960.8451615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:34TIKQTHSQY0.99960.8451615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:27TIKQTHSQY0.99960.8667615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:33TIKQTHSQY0.99960.8451615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:50TIKQTHSQY0.99950.8687615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:135TIKQTHSQY0.99950.8735615
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:31THSQYGMQL0.99940.94591019
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:02THSQYGMQL0.99930.97011019
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:39TIKQTHSQY0.9990.7375615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:35TIKQTHSQY0.99880.854615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:11TIKQTHSQY0.99880.7963615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:08TIKQTHSQY0.99870.8101615
KIF11-GRB14chr1094397302chr21653588452250HLA-B38:05THSQYGMQL0.99860.97721019
KIF11-GRB14chr1094397302chr21653588452250HLA-B35:11TIKQTHSQY0.99770.8343615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:24TIKQTHSQY0.99770.8688615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:12TIKQTHSQY0.99730.8987615
KIF11-GRB14chr1094397302chr21653588452250HLA-B35:43TIKQTHSQY0.99720.8115615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:09THSQYGMQL0.99460.92271019
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:53TIKQTHSQY0.99380.8401615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:13TIKQTHSQY0.98540.6255615
KIF11-GRB14chr1094397302chr21653588452250HLA-B57:04HSQYGMQLY0.98070.63561120
KIF11-GRB14chr1094397302chr21653588452250HLA-B58:06HSQYGMQLY0.96290.66561120
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:20TIKQTHSQY0.96280.8605615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:54TIKQTHSQY0.95480.8025615
KIF11-GRB14chr1094397302chr21653588452250HLA-B35:28TIKQTHSQY0.93210.8793615
KIF11-GRB14chr1094397302chr21653588452250HLA-C15:09HSQYGMQLY0.91920.73531120
KIF11-GRB14chr1094397302chr21653588452250HLA-B35:20TIKQTHSQY0.9180.8945615
KIF11-GRB14chr1094397302chr21653588452250HLA-C12:02TIKQTHSQY0.87930.9649615
KIF11-GRB14chr1094397302chr21653588452250HLA-C03:02TIKQTHSQY0.86030.9551615
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:11THSQYGMQL0.85980.93031019
KIF11-GRB14chr1094397302chr21653588452250HLA-C03:02HSQYGMQLY0.82210.94171120
KIF11-GRB14chr1094397302chr21653588452250HLA-A25:01TIKQTHSQY0.7690.8823615
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:01THSQYGMQL0.76450.69571019
KIF11-GRB14chr1094397302chr21653588452250HLA-C15:09TIKQTHSQY0.74780.844615
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:68TIKQTHSQY0.70460.5381615
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:17THSQYGMQL0.70390.96771019
KIF11-GRB14chr1094397302chr21653588452250HLA-C03:67THSQYGMQL0.68870.9671019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:22THSQYGMQL0.6170.73451019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:02THSQYGMQL0.54110.96031019
KIF11-GRB14chr1094397302chr21653588452250HLA-C07:04THSQYGMQL0.5210.93781019
KIF11-GRB14chr1094397302chr21653588452250HLA-A25:01HSQYGMQLY0.35330.71661120
KIF11-GRB14chr1094397302chr21653588452250HLA-C16:04HSQYGMQLY0.33190.94971120
KIF11-GRB14chr1094397302chr21653588452250HLA-C06:06THSQYGMQL0.32180.99221019
KIF11-GRB14chr1094397302chr21653588452250HLA-C16:01HSQYGMQLY0.27790.96121120
KIF11-GRB14chr1094397302chr21653588452250HLA-C16:02HSQYGMQLY0.25240.98611120
KIF11-GRB14chr1094397302chr21653588452250HLA-C02:02TIKQTHSQY0.20360.9729615
KIF11-GRB14chr1094397302chr21653588452250HLA-C02:10TIKQTHSQY0.20360.9729615
KIF11-GRB14chr1094397302chr21653588452250HLA-C12:02HSQYGMQLY0.16950.92771120
KIF11-GRB14chr1094397302chr21653588452250HLA-C02:02HSQYGMQLY0.05550.94411120
KIF11-GRB14chr1094397302chr21653588452250HLA-C02:10HSQYGMQLY0.05550.94411120
KIF11-GRB14chr1094397302chr21653588452250HLA-B40:12THSQYGMQL0.03950.58711019
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:34KTIKQTHSQY0.99960.8918515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:135KTIKQTHSQY0.99960.9244515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:125KTIKQTHSQY0.99960.8918515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:50KTIKQTHSQY0.99960.9163515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:27KTIKQTHSQY0.99960.9315515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:33KTIKQTHSQY0.99960.8918515
KIF11-GRB14chr1094397302chr21653588452250HLA-B57:10KTIKQTHSQY0.99950.9634515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:39KTIKQTHSQY0.99930.8117515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:35KTIKQTHSQY0.99920.8962515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:24KTIKQTHSQY0.99870.9426515
KIF11-GRB14chr1094397302chr21653588452250HLA-B57:04KTIKQTHSQY0.99850.7329515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:12KTIKQTHSQY0.99820.8787515
KIF11-GRB14chr1094397302chr21653588452250HLA-B58:06KTIKQTHSQY0.99710.835515
KIF11-GRB14chr1094397302chr21653588452250HLA-C15:09KTIKQTHSQY0.99210.8866515
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:20KTIKQTHSQY0.97170.9127515
KIF11-GRB14chr1094397302chr21653588452250HLA-A32:01KTIKQTHSQY0.91710.9635515
KIF11-GRB14chr1094397302chr21653588452250HLA-A30:01KTIKQTHSQY0.91180.9642515
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:11QTHSQYGMQL0.550.9365919
KIF11-GRB14chr1094397302chr21653588452250HLA-B39:31QTHSQYGMQL0.54310.9486919
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:09QTHSQYGMQL0.2740.9391919
KIF11-GRB14chr1094397302chr21653588452250HLA-B38:05QTHSQYGMQL0.2670.9754919
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:135SQYGMQLYQNY0.99990.84341223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:27SQYGMQLYQNY0.99990.84041223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:33SQYGMQLYQNY0.99990.82041223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:34SQYGMQLYQNY0.99990.82041223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:50SQYGMQLYQNY0.99990.82131223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:125SQYGMQLYQNY0.99990.82041223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:12SQYGMQLYQNY0.99980.83381223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:24SQYGMQLYQNY0.99970.80151223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:53SQYGMQLYQNY0.99950.78741223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:35SQYGMQLYQNY0.99880.79341223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:54SQYGMQLYQNY0.99460.7631223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:39SQYGMQLYQNY0.99380.75471223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:20SQYGMQLYQNY0.97040.89531223
KIF11-GRB14chr1094397302chr21653588452250HLA-B35:28SQYGMQLYQNY0.95670.92111223
KIF11-GRB14chr1094397302chr21653588452250HLA-B15:68LKTIKQTHSQY0.90390.5627415
KIF11-GRB14chr1094397302chr21653588452250HLA-B48:02SQYGMQLYQNY0.63240.90471223

Top

Potential FusionNeoAntigen Information of KIF11-GRB14 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
KIF11-GRB14_94397302_165358845.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
KIF11-GRB14chr1094397302chr21653588452250DRB1-0437DLKTIKQTHSQYGMQ318

Top

Fusion breakpoint peptide structures of KIF11-GRB14

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
9404TIKQTHSQYGMQLYKIF11GRB14chr1094397302chr21653588452250

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of KIF11-GRB14

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN9404TIKQTHSQYGMQLY-5.88662-6.12182
HLA-B14:023BVN9404TIKQTHSQYGMQLY-3.76987-4.43177
HLA-B52:013W399404TIKQTHSQYGMQLY-6.36635-6.60155
HLA-B52:013W399404TIKQTHSQYGMQLY-6.32482-6.98672
HLA-A11:014UQ29404TIKQTHSQYGMQLY-13.5638-14.2257
HLA-A24:025HGA9404TIKQTHSQYGMQLY-8.40605-8.64125
HLA-A24:025HGA9404TIKQTHSQYGMQLY-6.1189-6.7808
HLA-B27:056PYJ9404TIKQTHSQYGMQLY-9.31597-9.55117
HLA-B44:053DX89404TIKQTHSQYGMQLY-5.01868-5.68058
HLA-B44:053DX89404TIKQTHSQYGMQLY-4.43199-4.66719

Top

Vaccine Design for the FusionNeoAntigens of KIF11-GRB14

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
KIF11-GRB14chr1094397302chr21653588451019THSQYGMQLCATTCCCAGTATGGCATGCAGCTGTAC
KIF11-GRB14chr1094397302chr21653588451020THSQYGMQLYCATTCCCAGTATGGCATGCAGCTGTACCAG
KIF11-GRB14chr1094397302chr21653588451119HSQYGMQLTCCCAGTATGGCATGCAGCTGTAC
KIF11-GRB14chr1094397302chr21653588451120HSQYGMQLYTCCCAGTATGGCATGCAGCTGTACCAG
KIF11-GRB14chr1094397302chr21653588451220SQYGMQLYCAGTATGGCATGCAGCTGTACCAG
KIF11-GRB14chr1094397302chr21653588451223SQYGMQLYQNYCAGTATGGCATGCAGCTGTACCAGAATTATATG
KIF11-GRB14chr1094397302chr2165358845415LKTIKQTHSQYAAGACAATAAAGCAGACCCATTCCCAGTATGGC
KIF11-GRB14chr1094397302chr2165358845515KTIKQTHSQYACAATAAAGCAGACCCATTCCCAGTATGGC
KIF11-GRB14chr1094397302chr2165358845615TIKQTHSQYATAAAGCAGACCCATTCCCAGTATGGC
KIF11-GRB14chr1094397302chr2165358845715IKQTHSQYAAGCAGACCCATTCCCAGTATGGC
KIF11-GRB14chr1094397302chr2165358845817KQTHSQYGMCAGACCCATTCCCAGTATGGCATGCAG
KIF11-GRB14chr1094397302chr2165358845819KQTHSQYGMQLCAGACCCATTCCCAGTATGGCATGCAGCTGTAC
KIF11-GRB14chr1094397302chr2165358845919QTHSQYGMQLACCCATTCCCAGTATGGCATGCAGCTGTAC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
KIF11-GRB14chr1094397302chr2165358845318DLKTIKQTHSQYGMQCTGAAGACAATAAAGCAGACCCATTCCCAGTATGGCATGCAGCTG

Top

Information of the samples that have these potential fusion neoantigens of KIF11-GRB14

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADKIF11-GRB14chr1094397302ENST00000260731chr2165358845ENST00000263915TCGA-CD-8525-01A

Top

Potential target of CAR-T therapy development for KIF11-GRB14

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to KIF11-GRB14

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to KIF11-GRB14

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource